Parvovirus B19–Related Anemia in an HIV-Infected Patient: Rapid Control after Production of Neutralizing Antibodies during Highly Active Antiretroviral Therapy
Authors: Jose R. Arribas, Jose M. Peña, Juan E. Echevarría
Journal: Annals of Internal Medicine (2000)

Letters20 June 2000Parvovirus B19–Related Anemia in an HIV-Infected Patient: Rapid Control after Production of Neutralizing Antibodies during Highly Active Antiretroviral TherapyJose R. Arribas, MD, Jose M. Peña, MD, and Juan E. Echevarría, PhDJose R. Arribas, MDHospital La Paz; Madrid, Spain 28046 (Arribas)Hospital La Paz; Madrid, Spain 28046 (Peña)Instituto de Salud Carlos III; Madrid, Spain 28046 (Echevarría), Jose M. Peña, MDHospital La Paz; Madrid, Spain 28046 (Arribas)Hospital La Paz; Madrid, Spain 28046 (Peña)Instituto de Salud Carlos III; Madrid, Spain 28046 (Echevarría), and Juan E. Echevarría, PhDHospital La Paz; Madrid, Spain 28046 (Arribas)Hospital La Paz; Madrid, Spain 28046 (Peña)Instituto de Salud Carlos III; Madrid, Spain 28046 (Echevarría)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-12-200006200-00036 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Patients with AIDS cannot generate neutralizing antibodies against parvovirus B19 (1). Consequently, these patients can develop high-level parvovirus viremia, which is treated with repeated courses of intravenous immunoglobulin (IVIG). We describe an HIV-infected patient who mounted a primary immune response against parvovirus B19 after starting highly active antiretroviral therapy.A 31-year-old man was referred to our clinic because of recently diagnosed HIV infection. The hemoglobin level was 61 g/L, the CD4+ cell count was 0.02 cells × 109/L, and the HIV RNA level on polymerase chain reaction (PCR) was 14 700 copies/mL. Serum parvovirus IgG and IgM ...Reference1. Frickhofen N, Abkowitz JL, Safford M, Berry M, Antunez-de-Mayolo J, Astrow A, et al . Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med. 1990;113:926-33. LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: Jose R. Arribas, MD; Jose M. Peña, MD; Juan E. Echevarría, PhDAffiliations: Hospital La Paz; Madrid, Spain 28046 (Arribas)Hospital La Paz; Madrid, Spain 28046 (Peña)Instituto de Salud Carlos III; Madrid, Spain 28046 (Echevarría) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byParvovirus B19Intravenous Immunoglobulin Therapy for Pure Red Cell Aplasia Related to Human Parvovirus B19 Infection: A Retrospective Study of 10 Patients and Review of the LiteratureParvovirus B19 seroconversion in a cohort of human immunodeficiency virus-infected patientsPersistent parvovirus B19-induced anemia in an HIV-infected patient under HAART. Case report and review of literatureIntravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasiaPERSISTENT PARVOVIRUS-ASSOCIATED CHRONIC FATIGUE TREATED WITH HIGH DOSE INTRAVENOUS IMMUNOGLOBULINParvovirus B19 Encephalitis Presenting as Immune Restoration Disease after Highly Active Antiretroviral Therapy for Human Immunodeficiency Virus InfectionAntiviral Agents, DNASevere AnemiaFifth (human parvovirus) and sixth (herpesvirus 6) diseases 20 June 2000Volume 132, Issue 12 Page: 1011 Keywords Antibodies Hemoglobin Highly active antiretroviral therapy Immune response Intravenous immunoglobulin Plasma cells Polymerase chain reaction Red blood cells RNA Viremia ePublished: 15 August 2000 Issue Published: 20 June 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...